Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.

Epidemiologic studies suggest that some hormone-related risk factors in breast cancer differentially influence risk for disease subtypes classified by the status of the estrogen and progesterone receptors (ER/PR). However, it remains unclear whether human epidermal growth factor receptor 2 (HER2) or p53 expression status further differentiates these exposure-risk group associations. We evaluated the associations of oral contraceptive (OC) use and reproductive factors with incident invasive breast cancer subtypes among 1,197 population-based cases and 2,015 controls from the Los Angeles County or Detroit components of the Women's Contraceptive and Reproductive Experiences Study. Case-control comparisons by ER/PR/HER2/p53 status were conducted by multivariable polychotomous unconditional logistic regression methods. We found that OC use was not associated with any breast cancer subtype as defined by ER/PR/HER2/p53 status, except for a 2.9-fold increased risk of so-called triple-negative tumors (ER(-)/PR(-)/HER2(-)) among women of 45 to 64 years of age who started OC use before age 18. Parity was associated with a decreased risk of luminal A (ER(+) or PR(+), HER2(-)), luminal B (ER(+) or PR(+)/HER2(+)), and ER(-)/PR(-)/HER2(+) tumors. Age at first full-term pregnancy was positively associated with luminal A tumors among older women. Neither of these reproductive factors was associated with triple-negative tumors. Long duration of breast-feeding lowered the risk of triple-negative and luminal A tumors. p53 status did not define further differential risk patterns. Our findings offer evidence of differences in the hormone-related risk factors between triple-negative cancers and other ER/PR/HER2-defined subtypes of breast cancer.

[1]  R. Vihko,et al.  Estrogen and Progesterone Receptors in Breast Cancer , 1981, Acta obstetricia et gynecologica Scandinavica. Supplement.

[2]  G. Greene,et al.  Monoclonal antibodies as probes for estrogen receptor detection and characterization. , 1982, Journal of steroid biochemistry.

[3]  M. Press,et al.  An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[4]  M. Press,et al.  Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[5]  M. Press,et al.  Structure and dynamics of the estrogen receptor. , 1986, Journal of steroid biochemistry.

[6]  M. Press,et al.  Immunochemical Evaluation of Estrogen Receptor and Progesterone Receptor in Breast Cancer , 1987 .

[7]  R. Ceriani.  Immunological Approaches to the Diagnosis and Therapy of Breast Cancer , 1987, Springer US.

[8]  M. Press,et al.  Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. , 1988, Endocrinology.

[9]  J. Bacus,et al.  The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. , 1988, American journal of clinical pathology.

[10]  M. Press,et al.  Subcellular distribution of estrogen receptor and progesterone receptor with and without specific ligand. , 1989, The American journal of pathology.

[11]  J. Marks,et al.  Genetic basis for p53 overexpression in human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[13]  J. J. Li,et al.  Hormonal Carcinogenesis , 2020, Springer New York.

[14]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[15]  S. Fuqua,et al.  The p53 tumor-suppressor gene in human breast cancer. , 1994, Cancer treatment and research.

[16]  H. Smith.  Tumor-suppressor genes in breast cancer progression. , 1994, Cancer treatment and research.

[17]  H. Peterse,et al.  p53 protein overexpression in relation to risk factors for breast cancer. , 1996, American journal of epidemiology.

[18]  H. Peterse,et al.  p53 Protein Overexpression in Relation to Risk Factors for Breast Cancer , 1996 .

[19]  W. Thompson,et al.  Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  R. Kreienberg,et al.  p53 mutations and expression in ovarian cancers: correlation with overall survival. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  A. Reles,et al.  p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. , 2000, Gynecologic oncology.

[22]  N. Chobanyan.  Re: Henderson,B.E. and Feigelson,H.S. (2000) hormonal carcinogenesis. Carcinogenesis, 21, 427-433. , 2001, Carcinogenesis.

[23]  A. Fabiato,et al.  Anonymity of reviewers , 1994 .

[24]  T. Crook,et al.  The p53 pathway in breast cancer , 2002, Breast Cancer Research.

[25]  B. Friedenson.  Oral contraceptives and the risk of breast cancer. , 2002, The New England journal of medicine.

[26]  D. Edwards,et al.  Comparison of different antibodies for detection of progesterone receptor in breast cancer , 2002, Steroids.

[27]  Jinha M. Park,et al.  Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Wingo,et al.  The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. , 2002, Annals of epidemiology.

[29]  A. Chinnaiyan,et al.  Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. , 2003, Cancer research.

[30]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[31]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Wingo,et al.  Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women , 2003, Cancer Causes & Control.

[33]  M. García-Closas,et al.  Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  R. Millikan,et al.  Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States) , 2003, Cancer Causes & Control.

[35]  G. Dontu,et al.  Breast cancer, stem/progenitor cells and the estrogen receptor , 2004, Trends in Endocrinology & Metabolism.

[36]  B. Strom,et al.  Reproductive factors and risk of breast carcinoma in a study of white and African‐American women , 2004, Cancer.

[37]  Jinha M. Park,et al.  Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.

[38]  I. Runnebaum,et al.  Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas , 2005, International Journal of Gynecologic Cancer.

[39]  B. Strom,et al.  Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology , 2005, British Journal of Cancer.

[40]  D. Altshuler,et al.  Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. , 2006, Cancer research.

[41]  T. Sørlie,et al.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.

[42]  M. Pike,et al.  Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies , 2006, Breast Cancer Research.

[43]  B. Strom,et al.  Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Perou,et al.  Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.

[45]  M. García-Closas,et al.  Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[46]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[47]  P. Porter,et al.  Reproductive and hormonal risk factors for postmenopausal luminal, HER‐2‐overexpressing, and triple‐negative breast cancer , 2009, Cancer.

[48]  B. Strom,et al.  Breast Cancer Risk and Hormone Receptor Status in Older Women by Parity, Age of First Birth, and Breastfeeding: A Case-Control Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[49]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[50]  B. Strom,et al.  Breast Cancer Receptor Status: Do Results from a Centralized Pathology Laboratory Agree with SEER Registry Reports? , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[51]  L. Bernstein,et al.  Is There a Difference in the Association between Percent Mammographic Density and Subtypes of Breast Cancer? Luminal A and Triple-Negative Breast Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[52]  R. Coates,et al.  The epidemiology of triple-negative breast cancer, including race , 2009, Cancer Causes & Control.

[53]  L. Brinton,et al.  Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years , 2009, Cancer Epidemiology Biomarkers & Prevention.